Discontinue spironolactone several days prior to adrenal vein catheterization for measurement of aldosterone concentrations and measurements of plasma renin activity. Gynecomastia is observed not infrequently. In rare instances, gynecomastia may persist. Carcinoma of the breast has been reported in patients taking spironolactone, but a cause and effect relationship has not been established. A few cases of agranulocytosis have been reported in patients taking spironolactone.
Adverse reactions are usually reversible upon discontinuation of the drug.
These manifestations disappear promptly on discontinuation of medication. Hyperkalemia may be exacerbated. No persistent toxicity has occurred or is expected. Appearance of effects described above require only discontinuance of the drug. Induce vomiting and evacuate the stomach by lavage.